11th Member Earns Spot on Team's Roster in Celebration of the 11th Year of Team COPAXONE®
KANSAS CITY, Mo., Nov. 17, 2010 /PRNewswire/ -- Teva Neuroscience today announced the addition of an 11th member to Team COPAXONE® (glatiramer acetate injection); continuing a year-long celebration of the Team's 10 years of advocacy within the multiple sclerosis (MS) community. Jennifer Schuble, an elite track cyclist and member of the U.S. Paralympic Team, will join the Team's efforts in 2011 to promote a message of health and inspiration for those faced with an MS diagnosis. Team COPAXONE® comprises individuals living with MS who have strived to live their lives to the fullest despite their diagnosis. The Team works to educate MS patients nationwide about the benefits of a healthy diet and exercise with relapsing-remitting MS (RRMS).
See video from Teva Neuroscience at: http://inr.synapticdigital.com/TevaNeuro_37641/
"After my diagnosis in 2004, I made the decision to take action by doing my best to lead a healthy and active lifestyle," says Jennifer. "I've been blessed with the ability to cycle competitively despite MS, and have always been vocal about my story with the hope that it may inspire other patients to stay as active in whatever way they can. My new role on Team COPAXONE® will allow me to further inspire others living with RRMS, encourage dialogue and raise awareness about this disease."
Jennifer's cycling accolades consist of numerous American and World records, including a gold medal and two silver medals at the 2008 Beijing Paralympic Games and five Para-cycling World Championship titles.
Team COPAXONE® is a group of individuals with RRMS who have different talents and aspirations, yet one common objective: to live the lives they have imagined despite their disease. Jennifer exemplifies the Team's goal to change the perceptions society holds of people living with MS and to be actively engaging in a sport or pursuit they love. While individual results may vary, Jennifer aims to return to the Paralympic games in London in 2012, this time with the support of her Team COPAXONE® members behind her. Jennifer says, "I'm excited to join the ranks of these remarkable people who have contributed so much to the MS community."
"Teva Neuroscience is proud to honor the achievements of these extraordinary individuals whose unique accomplishments inspire and encourage those in the MS community, and beyond," said Jon Congleton, Vice President and General Manager of Teva Neuroscience. "We continue to celebrate the inspiring stories and successes of Team COPAXONE®, and we thank all individuals in the MS community who generously share their personal stories to help others face this disease."
Team COPAXONE® is sponsored by Teva Neuroscience, Inc. For more information on Jennifer and the members of Team COPAXONE®, please visit www.TeamCOPAXONE.com.
MS is a chronic, often disabling disease that attacks the central nervous system. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. In the U.S. today, there are approximately 400,000 people with MS — with 200 more people diagnosed every week. Worldwide, MS is thought to affect more than 2.1 million people. For more information on managing MS, including treatment and healthy living, visit www.SharedSolutions.com. Shared Solutions® is a network of resources available to everyone, and that includes people with MS, their CarePartners, friends, family, or anyone else who has been touched by MS.
COPAXONE® (glatiramer acetate injection) is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Additional Safety Information about COPAXONE®
The most common side effects of COPAXONE® are injection site reactions, such as redness, pain, swelling, itching, or a lump at the site of injection. A permanent indentation under the skin at the injection site may occur, due to a local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes. Some people report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. Keep in mind that these symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems. If symptoms become severe, call the emergency phone number in your area. Do not give yourself any more injections until your doctor tells you to begin again.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
COPAXONE® (glatiramer acetate injection) is now approved in 51 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In North America, COPAXONE® is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). In Europe, COPAXONE® is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd.
See additional important information at http://copaxone.com/pdf/PrescribingInformation.pdf or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.
About Teva Neuroscience
Teva Neuroscience is dedicated to investigating, developing and marketing ground-breaking products and technologies, with emphasis on cutting-edge treatments for patients who are living with neurological conditions, including multiple sclerosis (MS) and Parkinson's disease (PD). Therapies marketed by Teva Neuroscience include COPAXONE® (glatiramer acetate injection) for relapsing-remitting multiple sclerosis (RRMS) and Azilect® (rasagiline tablets) for the treatment of PD.
Teva Neuroscience's suite of innovative products continues to demonstrate the company's commitment to fulfilling unmet medical needs and has helped the company evolve into a global leader in RRMS. Teva Neuroscience is a North American division of Teva Pharmaceutical Industries Ltd., the world's largest generic drug company. Teva Neuroscience is proud of the role it plays in providing effective treatment options to patients worldwide. For more information, please visit www.tevaneuro.com or www.tevaclinicaltrials.com.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin®, Lotrel®, Protonix® and Yaz®, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions (including the acquisition of ratiopharm), interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission ("SEC")
Sr. Director, North America Corporate Communications
Contact: Synaptic Digital, New York
SOURCE Teva Neuroscience